QGEN
QIAGENCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The constructive read is that QIAGEN preserved adjusted EPS delivery in Q1 2026 despite weaker CER sales, management framed QuantiFERON weakness as a 2026 rebasing rather than a long-term impairment, and Baird upgraded the shares to Buy/Outperform on April 29, 2026 while cutting its target to $43, suggesting some investors may view the selloff as valuation reset rather than franchise break.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
QIAGEN's own forward-looking risk language flags product-development success, tariffs, currency, regulatory processes, customer funding variability, reimbursement/public-health funding and competition as ongoing risks to diagnostics and life-science growth [#6K-2026-04-27].
Momentum
50
Value
65
Sentiment
31
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $35.00 · Bull $39.00 · Bear $29.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $43.12
Why
Momentum50 · Δ7d +45.0
Value65 · Δ7d +0.0
Sentiment31 · Δ7d +1.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
50
26% active weight
Current posture
7d trendImproving
Δ7d
+45.0
Δ21d
+32.1
Value
65
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.5
Sentiment
31
34% active weight
Current posture
7d trendImproving
Δ7d
+1.7
Δ21d
-4.9
Why this grade
Composite grade C. Momentum 49.8 / Value 65.3 / Sentiment 31.1
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$8.36B
Beta
0.28
Shares Out
206.08M
P/E (TTM)
24.7
P/S (TTM)
4.77
P/FCF (TTM)
20.91
Rev YoY
+1.8%
EPS YoY
-24.9%
Gross Margin
+61.6%
Op Margin
+23.3%
Net Debt
$713.45M
Current Ratio
3.21
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology